Judo Bio develops oligonucleotide medicines that utilize its STRIKE platform to enable receptor-mediated uptake of siRNA specifically in kidney cells. The company's megalin-STRIKER programs target solute carrier proteins to reduce the accumulation of circulating solutes associated with systemic and renal diseases.
Funding
$105M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TFounders
Product
Problem
The kidney, a complex organ with diverse cell types, has historically been difficult to target with genetic medicines due to its intricate structure and the size barrier imposed by the glomerulus filtration. This lack of targeted delivery limits the treatment options for systemic and renal diseases.
Solution
Judo Bio is developing oligonucleotide medicines for kidney-specific delivery, enabling new treatments for systemic and renal diseases. The company's STRIKE (Selectively Targeting RNA Into KidnEy) platform creates ligand-RNA conjugate drugs designed for receptor-mediated uptake by specific kidney cell types, resulting in gene silencing of disease-modifying target genes. Judo Bio's initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule of the kidney to silence mRNA expression of specific solute carrier proteins (SLCs), thereby inhibiting the uptake of circulating solutes linked to systemic diseases. This approach overcomes the challenges of delivering oligonucleotide-based therapies to specific kidney cells.
Target Audience
The primary target audience includes patients with systemic and renal diseases, as well as researchers and clinicians focused on developing new treatments for these conditions.
Features
- STRIKE platform for targeted delivery of RNA therapeutics to the kidney
- Ligand-RNA conjugate drugs for receptor-mediated uptake by specific kidney cell types
- Megalin-STRIKERs that use the megalin receptor family for targeted delivery
- siRNA-based gene silencing strategies to address both systemic and renal diseases
- Programs targeting solute carrier proteins (SLCs) to reduce the accumulation of circulating solutes